Walleye Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Walleye Capital’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-167,701	Closed	-$391K	–	2830
2022 Q1	$391K	Buy	+167,701	New	+$523K	0.01%	1145
2021 Q2	–	Sell	-12,431	Closed	-$103K	–	1576
2021 Q1	$103K	Buy	+12,431	New	+$131K	0.01%	1032

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Walleye Capital's SRNE Position: Q2 2022 in Review

Walleye Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2022, closing a stake of 167,701 shares — an estimated $391K sold.

Walleye Capital first reported a position in SRNE in Q1 2021 and held it in 2 quarters. The position peaked at $391K in Q1 2022. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

Walleye Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Walleye Capital sold 167,701 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $391K.
Walleye Capital first reported a position in Sorrento Therapeutics, Inc. in Q1 2021 and held it in 2 quarters.
Walleye Capital's Sorrento Therapeutics, Inc. position peaked at $391K in Q1 2022.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.